X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Citi maintains buy ratings on Argentina power firms amid sector shifts
• Bernstein SocGen on StandardAero Inc (SARO): ' Solid revenues, but short-term margin issues'